Halozyme Therapeutics Inc (NAS:HALO)
$ 59.535 -0.075 (-0.13%) Market Cap: 7.57 Bil Enterprise Value: 8.45 Bil PE Ratio: 19.71 PB Ratio: 16.72 GF Score: 88/100

Halozyme Therapeutics Inc to Acquire Antares Pharma Inc to Create a Specialty Product and Drug Delivery Leader Call Transcript

Apr 13, 2022 / 12:00PM GMT
Release Date Price: $41.46 (-0.38%)
Operator

Good morning. My name is Rob, and I will be your conference operator today. At this time, I would like to welcome everyone to the Halozyme Conference Call and Webcast. (Operator Instructions)

Dawn Schottlandt, you may begin your conference.

Dawn Schottlandt
Argot Partners, LLC - SVP

Thank you, and good morning, everyone. Thank you for joining our call today to discuss Halozyme's acquisition of Antares Pharma. Joining me today is Dr. Helen Torley, Halozyme's President and Chief Executive Officer; Nicole LaBrosse, Halozyme's Chief Financial Officer, is also joining for the question-and-answer session.

As a reminder, this call is being recorded, and the press release and slide presentation regarding today's news are available on the Investor Relations section of Halozyme and Antares respective websites. This communication is not intended to constitute an offer to buy or sell or the solicitation of an offer to buy any securities or solicitation of any vote or approval. Antares intends to file (inaudible) with the SEC regarding the proposed

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot